Disease-Modifying Therapies for Relapsing–Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis

MS medication cost and effectiveness summary: https://t.co/Uj1Cy1aGQW

@pash22 Courtesy of https://t.co/EYHi7tYhIg Although @JoshJCarlson name on there so we should double check those numbers! ;)

RT @OhioHealthMS: "Alemtuzumab dominated other options for 2nd line treatment of RRMS. Other DMTs were generally similar in terms of costs…

RT @OhioHealthMS: "Alemtuzumab dominated other options for second-line treatment of RRMS" Disease-Modifying Therapies for RR & PPMS: A Cost…

"Alemtuzumab dominated other options for 2nd line treatment of RRMS. Other DMTs were generally similar in terms of costs & health outcomes, providing health benefits compared to supportive care but w/ significant added costs" https://t.co/ziNA4RBIjw ht

RT @OhioHealthMS: Read This: "Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utilit…

RT @OhioHealthMS: Read This: "Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utilit…

RT @hcanes100: Amen https://t.co/WzovYGfHW9

Amen

RT @OhioHealthMS: "Alemtuzumab dominated other options for second-line treatment of RRMS" Disease-Modifying Therapies for RR & PPMS: A Cost…

"Alemtuzumab dominated other options for second-line treatment of RRMS" Disease-Modifying Therapies for RR & PPMS: A Cost-Utility Analysis. https://t.co/nLmu79Pywh https://t.co/jArXJVy6OO

RT @OhioHealthMS: Read This: "Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utilit…

You are not kidding!

Read This: "Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis" https://t.co/UObTPZhP9m https://t.co/hG9iECZT7T

Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis. https://t.co/p1jFGPaQ3t